Abstract
AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined.
Abbreviations | ||
HDM/SCT | = | high-dose melphalan and stem cell transplantation |
CR | = | hematologic complete response |
FLC | = | serum free light chain concentration |
TRM | = | treatment-related mortality |
Abbreviations | ||
HDM/SCT | = | high-dose melphalan and stem cell transplantation |
CR | = | hematologic complete response |
FLC | = | serum free light chain concentration |
TRM | = | treatment-related mortality |